Abstract:Our objective was to develop an array of alpha(7)-selective nicotinic cholinergic receptor (nAChR)-based imaging agents for PET and SPECT. Methods: (2'R)-N-C-11-Methyl-N-(phenylmethyl)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-amine 1 was synthesized by reaction of the corresponding desmethyl precursor with C-11-CO2 and reduction. N-(R)-1-Aza-bicyclo[2.2.2]oct-3-yl-4-C-11-methylsulfanyl-benzamide 2 was synthesized by reduction of the corresponding disulfide precursor and reaction with C-11-iodomethane. N-(R)-1-Aza-bicyclo[2.2.2]oct-3-yl-4-'251-iodo-benzamide 3 was synthesized by halogen exchange of the corresponding bromide. (2'R)-5'-(2-I-125-iodo-3-furanyl)spiro[1-azabicyclo[2.2.2] octane]-3,2'(3'H)-furo[2,3-b]pyridine 4 was synthesized by the chloramine-T method. Kinetic biodistribution studies were done in male CD-1 mice by tail vein injection of 3.7 MBq (100 muCi) of the C-11-labeled radiotracer or 0.67 MBq (2 muCi) of the I-125-labeled radiotracer followed by brain dissection and tissue counting. Receptor blockade was determined by pretreatment of the mice with an excess of either unlabeled precursor or nicotine. Results: We synthesized 4 radiolabeled, moderate- to high-affinity, mu(7)-nAChR-based ligands. The compounds were a series of quinuclidine derivatives with an inhibition constant (K-i) < 6 nmol/L (33 pmol/L for 4) for alpha(7)-nAChR and selectivities of alpha(7)/alpha(4)beta(2) subtypes of greater than or equal to 14,000. All of the compounds were produced in adequate radiochemical yield and specific radioactivity (>74 GBq/mumol [2,000 Ci/mmol]). No site selectivity or receptor blockade was shown for 1 and 2 (0.91 +/- 0.05 and 0.14 +/- 0.03 %ID/g [percentage injected dose per gram] in the hippocampus [target tissue], respectively). Compound 3 showed low hippocampal uptake (0.25 +/- 0.05 %ID/g) but prolonged retention within that structure. Pretreatment with nicotine decreased its uptake by up to 50% in the hippocampus. Similar reductions were also observed within the cerebellum (nontarget tissue). Compound 4 showed hippocampal uptake of 2.41 +/- 0.03 %ID/g and target-to-nontarget uptake ratios of up to 2. Pretreatment of animals with unlabeled 4 resulted in a decrease of hippocampal uptake to 60% of its preblockade value without a corresponding decrease in cerebellar uptake. Conclusion: With further structural optimization, selective imaging of a7-nAChR may be possible.

Different interaction between the agonist JN403 and the competitive antagonist methyllycaconitine with the human alpha7 nicotinic acetylcholine receptor

Different Interaction Between The Agonist Jn403 And The Competitive Antagonist Methyllycaconitine With The Human Alpha 7 Nicotinic Acetylcholine Receptor

Novel Positive Allosteric Modulators of the Human Α7 Nicotinic Acetylcholine Receptor

Pharmacological Properties and Evaluations of a Novel Positive Allosteric Modulator of Α7 Nachr for Attenuation of Schizophrenia-Like Behavior in Mice

Partial Activation of Α7 Nicotinic Acetylcholine Receptors: Insights from Molecular Dynamics Simulations.

Differentiation of the Agonists and Antagonists of the α7 Nicotinic Acetylcholine Receptor

Novel interplay between agonist and calcium binding sites modulates drug potentiation of α7 acetylcholine receptor

Identification and in Vitro Pharmacological Characterization of a Novel and Selective Α7 Nicotinic Acetylcholine Receptor Agonist, Br-IQ17B

The Subtype-Selective Nicotinic Acetylcholine Receptor Positive Allosteric Potentiator 2087101 Differentially Facilitates Neurotransmission in the Brain.

Engineered Conotoxin Differentially Blocks and Discriminates Rat and Human α7 Nicotinic Acetylcholine Receptors

Synthesis and Biological Evaluation of Novel Hybrids of Highly Potent and Selective Α4β2-Nicotinic Acetylcholine Receptor (nachr) Partial Agonists.

The α7 nAChR selective agonists as drug candidates for Alzheimer's disease.

High Selectivity Of An Alpha-Conotoxin Lvia Analogue For Alpha 3 Beta 2 Nicotinic Acetylcholine Receptors Is Mediated By Beta 2 Functionally Important Residues

Synthesis and Biological Evaluation of Novel Triazine Derivatives as Positive Allosteric Modulators of α7 Nicotinic Acetylcholine Receptors

Preclinical Characterization of A-582941: A Novel Α7 Neuronal Nicotinic Receptor Agonist with Broad Spectrum Cognition-Enhancing Properties

A Novel Alpha 4/7-Conotoxin Lvia From Conus Lividus That Selectively Blocks Alpha 3 Beta 2 Vs. Alpha 6/Alpha 3 Beta 2 Beta 3 Nicotinic Acetylcholine Receptors

Preclinical Characterization Of A-582941: A Novel Alpha 7 Neuronal Nicotinic Receptor Agonist With Broad Spectrum Cognition-Enhancing Properties

Species differences and mechanism of action of A3 adenosine receptor allosteric modulators

Mechanism of Action and Structure-Activity Relationship of a-Conotoxin Mr1.1 at the Human a9a10 Nicotinic Acetylcholine Receptor

Chemistry And Pharmacological Characterization Of Novel Nitrogen Analogues Of Amop-H-Oh (Sazetidine-A, 6[5-(Azetidin-2-Ylmethoxy)Pyridin-3-Yl]Hex-5-Yn-L-Ol) As Alpha 4 Beta 2-Nicotinic Acetylcholine Receptor-Selective Partial Agonists

Synthesis and biodistribution of radiolabeled alpha 7 nicotinic acetylcholine receptor ligands.